# COVID-19 Vaccination in a Patient With Gluten Enteropathy: A Case Report

## TL;DR

A 15-year-old girl with gluten enteropathy safely received the Covaxin vaccine without adverse reactions.

## Contribution

This case report is the first to document the safe administration of Covaxin to a gluten enteropathy patient.

## Key findings

- The patient showed no adverse events after receiving the first dose of Covaxin.
- No prior cases of Covaxin vaccination in gluten enteropathy patients have been reported.
- Proper medical supervision and history-taking are essential for safe vaccination in allergy-prone individuals.

## Abstract

In India, the COVID-19 vaccination for adolescents aged 15-17 years has been started since January 2022. Gluten enteropathy, also known as celiac or nontropical sprue, can arise as an autoimmune disease of the small intestines. We report a 15-year-old female with a history of allergy to gluten-containing products who came for the first dose of the COVID-19 vaccination to adult vaccination OPD at All India Institute of Medical Sciences, Jodhpur. After taking a detailed history, she had an allergy to gluten-containing products for five years. She had no previous history of allergic reactions to injections or medicines. The first dose of Covaxin was given to this female under proper supervision, and she was followed up for any adverse events. We did not find any evidence of adverse events following the COVID-19 vaccination in people with gluten enteropathy. The patient was discharged after one hour of observation. To date, no cases of Covaxin vaccination have been reported among gluten enteropathy patients. We discuss the current evidence relating to Covaxin vaccinations, highlighting that administering the vaccine to gluten-sensitive individuals did not cause any adverse reactions. However, proper history taking and other standard procedures should be followed while administering Covaxin to any known allergies.